Cancer Radiotherapie最新文献

{"title":"Impact of adjuvant radiotherapy and chemotherapy on thymoma","authors":"J. Dumont ,&nbsp;J. Bou-Gharios ,&nbsp;A. Keller ,&nbsp;I. Chambrelant ,&nbsp;G. Pamart ,&nbsp;C. Mascaux ,&nbsp;P.-E. Falcoz ,&nbsp;D. Antoni ,&nbsp;A. Olland ,&nbsp;G.A. Pietta ,&nbsp;G. Noël","doi":"10.1016/j.canrad.2023.08.009","DOIUrl":"10.1016/j.canrad.2023.08.009","url":null,"abstract":"<div><h3>Purpose</h3><p>Thymoma is a rare tumour. The most common treatment for thymoma is surgical resection, while the use of radiotherapy and chemotherapy remains controversial.</p></div><div><h3>Patients and methods</h3><p>We conducted a monocentric observational study of 31 patients diagnosed with thymoma from June 2004 to July 2020 at cancer centre in Strasbourg, France. We analysed the outcomes of the patients.</p></div><div><h3>Results</h3><p>The 2- and 5- year locoregional relapse-free survival rates were 96.3% (95% confidence interval [CI]: 76.5–99.5%) and 68.0% (95% CI: 43.8–83.5%), respectively. Radiotherapy and chemotherapy significantly improved local tumour control (<em>P</em> <!-->=<!--> <!-->0.0008 and 0.04, respectively), while a larger initial tumour size significantly worsened local control rates (<em>P</em> <!-->=<!--> <!-->0.04). The 5- and 10-year overall survival rates were 87.1% (95% CI: 69.2–95%) and 81.7% (95% CI: 60.3–92.2%), respectively. The median overall survival was not reached, and no favourable factor was retrieved. For relapsed patients, the median overall survival after relapse was 115 months.</p></div><div><h3>Conclusion</h3><p>Despite the inherent limitations of retrospective studies with a limited patient sample size, we demonstrated that chemotherapy and radiotherapy in addition to surgery were effective in achieving local control and contributed to improving patient outcomes in thymoma. Notably, an aggressive treatment strategy at the time of relapse resulted in favourable outcomes for retreated patients.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 174-181"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139096167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality control of postoperative radiotherapy for non-small cell lung cancer: A study of mediastinal shift","authors":"W. Zhang ,&nbsp;Y. Zhang ,&nbsp;W.-W. Ouyang ,&nbsp;S. Fa Su ,&nbsp;Z. Ma ,&nbsp;Q.-S. Li ,&nbsp;W. Gang Yang ,&nbsp;X. Xia Chen ,&nbsp;J. Liu ,&nbsp;B. Lu","doi":"10.1016/j.canrad.2023.06.032","DOIUrl":"10.1016/j.canrad.2023.06.032","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;p&gt;This study aimed to assess the shifting patterns of the mediastinum, including the target volume and the isocenter point during the postoperative radiotherapy (PORT) process of non-small cell lung cancer (NSCLC), and to observe the occurrence of radiation injury. Additionally, we investigated the significance of mid-term assessment during the implementation of the PORT process.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Material and methods&lt;/h3&gt;&lt;p&gt;We established coordinate axes based on bone anatomy and measured the mediastinum's three-dimensional direction and the shift of the isocenter point's shift in the PORT process. Statistical analysis was performed using Wilcoxon, Kruskal-Wallis, and the Chi-square test. &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0.05 was considered statistically significant.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;In this study, the analysis of patients revealed that the shift of anterior and posterior mediastinum (X), left and right mediastinum (Y), upper and lower mediastinum (Z), anterior and posterior isocenter point (X&lt;sub&gt;i&lt;/sub&gt;), and the left and right isocenter points (Y&lt;sub&gt;i&lt;/sub&gt;) in the PORT process were 0.04–0.53, 0.00–0.84, 0.00–1.27, 0.01–0.86, and 0.00–0.66&lt;!--&gt; &lt;!--&gt;cm, respectively. The shift distance of the mediastinum was Z&lt;!--&gt; &lt;!--&gt;&gt;&lt;!--&gt; &lt;!--&gt;Y&lt;!--&gt; &lt;!--&gt;&gt;&lt;!--&gt; &lt;!--&gt;X, and the shift distance of the isocenter point was X&lt;sub&gt;i&lt;/sub&gt; &lt;!--&gt;&gt;&lt;!--&gt; &lt;!--&gt;Y&lt;sub&gt;i&lt;/sub&gt;. According to the ROC curve, the cut-off values were 0.263, 0.352, 0.405, 0.238, and 0.258, respectively, which were more significant than the cut-off values in 25 cases (25%), 30 cases (30%), 30 cases (30%), 17 cases (17%), and 15 cases (15%). In addition, there was a significant difference in the shift of the mediastinum and the isocenter point (all &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.00). Kruskal-Wallis test showed no statistically significant difference between mediastinal shift and resection site in X, Y, and Z directions (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.355, &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.239, &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.256), surgical method (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.241, &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.110, &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.064). There was no significant difference in the incidence of RE and RP in PORT patients (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;&gt;&lt;!--&gt; &lt;!--&gt;0.05). No III–IV RP occurred. However, the incidence of ≥ grade III RE in the modified plan cases after M-S was significantly lower than in the original PORT patients, 0% and 7%, respectively (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.000).&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;In conclusion, this study provides evidence that mediastinal shift is a potential complication during the PORT process for patients with N2 stage or R1–2 resection following radical resection of NSCLC. This shift affects about 20–30% of patients, manifesting as actual radiation damage to normal tissue and reducing the local control rate. Therefore, mid-term repositioning of the PORT and revision of the target volume and radiation thera","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 152-158"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139699133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment","authors":"M. Cuenin ,&nbsp;J. Salleron ,&nbsp;D. Peiffert ,&nbsp;É. Meknaci ,&nbsp;P. Gallet ,&nbsp;Y. Abushama ,&nbsp;J.-F. Py ,&nbsp;S. Renard","doi":"10.1016/j.canrad.2023.06.031","DOIUrl":"10.1016/j.canrad.2023.06.031","url":null,"abstract":"<div><h3>Purpose</h3><p>Low-dose-rate (LDR) and high-dose-rate (HDR) interstitial brachytherapy are known to be effective in the treatment of lip carcinomas. The aim of this study was to retrospectively compare oncologic and toxicity outcomes between the two techniques.</p></div><div><h3>Patients and methods</h3><p>From 2007 to 2018, patients at the Institut de cancérologie de Lorraine (France) who received exclusive or adjuvant interstitial brachytherapy for lip squamous carcinomas were studied. Two groups were defined: the LDR/PDR group, including patients treated with iridium-192 wires, or pulsed-dose rate technique, and the high-dose-rate group, with patients treated by high-dose-rate technique. The dose ranged between 50<!--> <!-->Gy and 65<!--> <!-->Gy (depending on previous surgery) for low-dose-/pulsed-dose rate treatments, and 39<!--> <!-->Gy for high-dose-rate (twice a day). Early, late toxicity events and oncologic control were reported.</p></div><div><h3>Results</h3><p>Among the 61 patients whose data were analyzed retrospectively, 36 received the low-dose-/pulsed-dose rate treatment (59%) and 25 the high-dose-rate brachytherapy (41%). The median follow-up time was 44 months. At 36 months, the local control rates were 96.3% for LDR/PDR group and 100% for HDR (<em>P</em> <!-->=<!--> <!-->0.180). The regional control rates were 85.9% and 92% without any difference according to the two groups (<em>P</em> <!-->=<!--> <!-->0.179). The specific overall survival rate was 95.5% with no difference between groups. There were more grade 2 or higher mucositis in the HDR group than in LDR/PDR group (40% versus 16.7%, <em>P</em> <!-->=<!--> <!-->0.042). One case of grade 3 mucositis was recorded in each group. No grade 3 late complications were recorded. High-dose-rate brachytherapy reduced the length of hospitalization by 2 days (<em>P</em> <!-->&lt;<!--> <!-->0.001).</p></div><div><h3>Conclusion</h3><p>High-dose- or low-dose-/pulsed-dose rate brachytherapy seemed to be as effective and well tolerated in our experience of 61 patients.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 145-151"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138568530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on “An umbrella review exploring the effect of radiotherapy for head and neck cancer patients on the frequency of jaws osteoradionecrosis”","authors":"B. Yilmaz ,&nbsp;U. Selek","doi":"10.1016/j.canrad.2023.07.016","DOIUrl":"10.1016/j.canrad.2023.07.016","url":null,"abstract":"","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 206-207"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2023 A new French revolution: Organ preservation for rectal cancer","authors":"J.-P. Gérard","doi":"10.1016/j.canrad.2024.02.001","DOIUrl":"10.1016/j.canrad.2024.02.001","url":null,"abstract":"","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 143-144"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140178179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proposition de délinéation des volumes cibles anatomocliniques postopératoires de la tumeur primitive des cancers du sinus maxillaire et des cavités nasales","authors":"F. Guillemin ,&nbsp;P. Blanchard ,&nbsp;P. Boisselier ,&nbsp;Y. Brahimi ,&nbsp;V. Calugaru ,&nbsp;A. Coutte ,&nbsp;P. Gillon ,&nbsp;P. Graff ,&nbsp;X. Liem ,&nbsp;A. Modesto ,&nbsp;Y. Pointreau ,&nbsp;S. Racadot ,&nbsp;X.S. Sun ,&nbsp;R. Bellini ,&nbsp;N. Pham Dang ,&nbsp;N. Saroul ,&nbsp;J. Bourhis ,&nbsp;J. Thariat ,&nbsp;J. Biau ,&nbsp;M. Lapeyre","doi":"10.1016/j.canrad.2023.12.001","DOIUrl":"https://doi.org/10.1016/j.canrad.2023.12.001","url":null,"abstract":"<div><p>In this article, we propose a consensus delineation of postoperative clinical target volumes for the primary tumour in maxillary sinus and nasal cavity cancers. These guidelines are developed based on radioanatomy and the natural history of those cancers. They require the fusion of the planning CT with preoperative imaging for accurate positioning of the initial GTV and the combined use of the geometric and anatomical concepts for the delineation of clinical target volume for the primary tumour. This article does not discuss the indications of external radiotherapy (nor concurrent systemic treatment) but focuses on target volumes when there is an indication for radiotherapy.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 218-227"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140605937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute toxicity in patients with high-risk prostate cancer treated with stereotactic body radiation, with irradiation to the prostate and pelvic nodes","authors":"S. Faria ,&nbsp;M. Duclos ,&nbsp;F. Cury ,&nbsp;H. Patrocinio ,&nbsp;L. Souhami","doi":"10.1016/j.canrad.2023.07.014","DOIUrl":"10.1016/j.canrad.2023.07.014","url":null,"abstract":"<div><h3>Purpose</h3><p>Stereotactic body radiation therapy has been used for prostate cancer. However, the bulk of published studies on stereotactic body radiation therapy for prostate cancer has involved the irradiation of the prostate alone, without irradiation of the pelvic lymph nodes. We report our preliminary experience with this approach.</p></div><div><h3>Material and methods</h3><p>The files of patients with biopsy-proven prostate cancer treated with stereotactic body radiation therapy in our institution were reviewed. Stereotactic body radiation was delivered with intensity modulated-volumetric arctherapy with daily image-guidance. The prostate planning target volume included the prostate plus a margin of 5<!--> <!-->mm in all directions. The pelvic planning target volume included pelvic nodes plus an expansion of 6 to 7<!--> <!-->mm in all directions. The prostate planning target volume received a total dose of 36.25<!--> <!-->Gy delivered in five fractions on alternate days. The nodal planning target volume received a dose of 25<!--> <!-->Gy in the same five fractions. Patients were followed during treatment, after 1, and 3 months and every 6 months thereafter. Gastrointestinal and genitourinary toxicity was prospectively graded according to Common Terminology Criteria for Adverse Events.</p></div><div><h3>Results</h3><p>Among the 188 patients, 80 received stereotactic body radiation to the prostate and the pelvic nodes, while 108 received stereotactic body radiation to the prostate target only. Grade 2 acute gastrointestinal toxicity was 4% in both groups, and grade 2 acute genitourinary toxicity was 27% and 20% (<em>P</em> <!-->=<!--> <!-->0.9) for prostate only versus prostate and pelvis respectively. There was no grade 3 or higher acute gastrointestinal or genitourinary toxicity.</p></div><div><h3>Conclusion</h3><p>Stereotactic body radiation therapy in five fractions including the prostate and pelvic nodes, in patients with high-risk prostate cancer, has been feasible and safe in terms of acute toxicity.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 159-163"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140320122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy in the management of lung oligometastases","authors":"V. Bourbonne ,&nbsp;A. Lévy ,&nbsp;J. Khalifa ,&nbsp;D. Antoni ,&nbsp;E. Blais ,&nbsp;J. Darréon ,&nbsp;C. Le Péchoux ,&nbsp;D. Lerouge ,&nbsp;P. Giraud ,&nbsp;A. Marguerit ,&nbsp;N. Pourel ,&nbsp;F.-G. Riet ,&nbsp;S. Thureau","doi":"10.1016/j.canrad.2023.06.030","DOIUrl":"10.1016/j.canrad.2023.06.030","url":null,"abstract":"<div><p>In recent years, the development of both medical imaging and new systemic agents (targeted therapy and immunotherapy) have revolutionized the field of oncology, leading to a new entity: oligometastatic disease. Adding local treatment of oligometastases to systemic treatment could lead to prolonged survival with no significant impact on quality of life. Given the high prevalence of lung oligometastases and the new systemic agents coming with increased pulmonary toxicity, this article provides a comprehensive review of the current state-of-art for radiotherapy of lung oligometastases. After reviewing pretreatment workup, the authors define several radiotherapy regimen based on the localization and size of the oligometastases. A comment on the synergistic combination of medical treatment and radiotherapy is also made, projecting on future steps in this specific clinical setting.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 1","pages":"Pages 36-48"},"PeriodicalIF":1.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139477137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation therapy of the primary tumour and/or metastases of digestive metastatic cancers","authors":"F. Huguet ,&nbsp;O. Riou ,&nbsp;D. Pasquier ,&nbsp;A. Modesto ,&nbsp;L. Quéro ,&nbsp;M. Michalet ,&nbsp;A. Bordron ,&nbsp;B. Schipman ,&nbsp;A. Orthuon ,&nbsp;A. Lisbona ,&nbsp;V. Vendrely ,&nbsp;N. Jaksic","doi":"10.1016/j.canrad.2023.04.007","DOIUrl":"10.1016/j.canrad.2023.04.007","url":null,"abstract":"<div><p>Metastatic gastrointestinal cancer is not an uncommon situation, especially for pancreatic, gastric, and colorectal cancers. In this setting, few data are available on the impact of the treatment of the primary tumour. Oligometastatic disease is associated with longer survival in comparison with more advanced disease. Metastasis-directed therapy, such as stereotactic body radiotherapy, seems related to better outcomes, but the level of evidence is low. In most tumour locations, prospective data are very scarce and inclusion in ongoing trials is strongly recommended.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 1","pages":"Pages 66-74"},"PeriodicalIF":1.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41175602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy in the management of synchronous metastatic lung cancer","authors":"J. Khalifa ,&nbsp;A. Lévy ,&nbsp;L.-M. Sauvage ,&nbsp;S. Thureau ,&nbsp;J. Darréon ,&nbsp;C. Le Péchoux ,&nbsp;D. Lerouge ,&nbsp;N. Pourel ,&nbsp;D. Antoni ,&nbsp;E. Blais ,&nbsp;É. Martin ,&nbsp;A. Marguerit ,&nbsp;P. Giraud ,&nbsp;F.-G. Riet","doi":"10.1016/j.canrad.2023.03.002","DOIUrl":"10.1016/j.canrad.2023.03.002","url":null,"abstract":"<div><p>Metastatic lung cancer classically portends a poor prognosis. The management of metastatic lung cancer has dramatically changed with the emergence of immune checkpoint inhibitors, targeted therapy and due to a better understanding of the oligometastatic process. In metastatic lung cancers, radiation therapy which was only used with palliative intent for decades, represents today a promising way to treat primary and oligometastatic sites with a curative intent. Herein we present through a literature review the role of radiotherapy in the management of synchronous metastatic lung cancers.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 1","pages":"Pages 22-35"},"PeriodicalIF":1.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9981475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}